Anomalous HIV-1 RNA, How Cap-Methylation Segregates Viral Transcripts by Form and Function

Kathleen Boris-Lawrie 1,*, Gatikrushna Singh 1,2, Patrick S. Osmer 3, Dora Zucko 1, Seth Staller 4 and Xiao Heng 4,*

1 Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108, USA; gsingh@umn.edu (G.S.); zucko001@umn.edu (D.Z.)
2 Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA
3 Department of Astronomy, The Ohio State University, Columbus, OH 43210, USA; osmer.1@osu.edu
4 Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA; saspn4@mail.missouri.edu
* Correspondence: kbl@umn.edu (K.B.-L.); hengx@missouri.edu (X.H.); Tel.: +1-612-625-2100 (K.B.-L.)

Abstract: The acquisition of m\(^7\)G-cap-binding proteins is now recognized as a major variable driving the form and function of host RNAs. This manuscript compares the 5′-cap-RNA binding proteins that engage HIV-1 precursor RNAs, host mRNAs, small nuclear (sn)- and small nucleolar (sno) RNAs and sort into disparate RNA-fate pathways. Before completion of the transcription cycle, the transcription start site of nascent class II RNAs is appended to a non-templated guanosine that is methylated (m\(^7\)G-cap) and bound by hetero-dimeric CBP80-CBP20 cap binding complex (CBC). The CBC is a nexus for the co-transcriptional processing of precursor RNAs to mRNAs and the snRNA and snoRNA of spliceosomal and ribosomal ribonucleoproteins (RNPs). Just as sn/sno-RNAs experience hyper-methylation of m\(^7\)G-cap to trimethylguanosine (TMG)-cap, so do select HIV RNAs and an emerging cohort of mRNAs. TMG-cap is blocked from Watson:Crick base pairing and disqualified from participating in secondary structure. The HIV TMG-cap has been shown to license select viral transcripts for specialized cap-dependent translation initiation without eIF4E that is dependent upon CBP80/NCBP3. The exceptional activity of HIV precursor RNAs secures their access to maturation pathways of sn/snoRNAs, canonical and non-canonical host mRNAs in proper stoichiometry to execute the retroviral replication cycle.

Keywords: epigenetic modification; internal ribosome entry; junD; NCBP3; RNA virus; ribosome scanning; specialized translation; trimethylguanosine (TMG) cap

1. Introduction

1.1. Anomalous HIV RNAs Are Indispensable to Carry out the Retroviral Replication Cycle

Hosts support every step of the HIV-1 (HIV) replication cycle [1]. Vast evidence has shown retroviral precursor RNAs subvert the mRNA metabolism pathways of hosts [2]. The subversive behavior of HIV RNAs originates from primary sequence content and dynamic intramolecular structural content [3]. By sorting of nascent HIV transcripts into host ribonucleoprotein (RNPs), HIV precursors engage host maturation pathways of both mRNAs and non-coding RNAs. As a result, the 9000 nucleotide (nt) HIV precursor RNA manifests exceptional coding capacity. The RNA-protein interactions necessary for the anomalous activity of HIV precursor RNA are the focus of this article.

1.2. The Biogenesis of HIV RNA Is Aligned with the Biogenesis of Host Noncoding RNA and Protein Coding RNA

The combined activity of RNA polymerase (RNAP) I, II and III is required to synthesize the host transcriptome. The majority of RNA products are noncoding RNAs and ultimately just 4% of the products become mRNA templates translated to protein [3]. Vastly
outnumbered, the expression of the protein-coding transcripts requires RNA fate pathways that govern the maturation of noncoding RNAs [3].

RNAPII synthesizes precursor mRNAs, but most of its products are precursor small nuclear RNAs (snRNAs) and nucleolar RNAs (snoRNAs). Emerging from the same process of class II gene transcription, the noncoding RNAs enter distinct maturation pathways from protein-coding RNAs. They obtain unique epigenetic modifications and segregate with nucleolar RNP that guide the assembly of massive RNA-protein machineries (spliceosomes and ribosomes) or cytoplasmic RNP that translate mature mRNA. The hallmark events in the lives of snRNA, snoRNA and mRNA commence with co-transcriptional loading of similar RNA binding proteins, but come to fruition by different trafficking pathways and epigenetic modifications that license different RNA fates.

The HIV precursors share trafficking pathways with host sn/snoRNAs and mRNAs. One 9000 nucleotide full length HIV RNA encodes regulatory, accessory and structural proteins and dimeric genomic RNA. Full understanding of the anomalous RNA fates is a pressing goal in virology. Fulfillment is to have broad ramifications by exposing host aberrations affecting human health and originating new targets and RNA-directed therapeutics to cure HIV disease.

The functional plasticity of HIV-1 primary RNA has been attributed to shape-shifting of the 5′-untranslated region (UTR) [4,5]. Intense examinations have documented significant interplay between co-transcriptional host RNP assembly and the fate of mature HIV RNAs in productive infection [2]. Structural variables at the 5′-UTR of noncoding RNAs have been shown to affect function too [6–8]. For instance, snRNAs require nt-nt pairings within the 5′-Sm site [consensus PuA(U)_{4–6}GPu], which engenders the hypermethylation of the 5′-cap (more below). The essential cis-acting structural motifs near the TSS of snoRNAs require nt-nt pairings within Box C (C′ in U3 snoRNA), which engender the hypermethylation of the snoRNA 5′-cap. The different energetically-tenable shapes within the 5′-UTR of sn/snoRNAs are necessary for the epigenetic modification of the 5′-cap.

2. HIV Precursor RNAs Enter Mutually Exclusive RNA-Fate Pathways during Transcription

2.1. Two-Phase Transcriptional Programming Originates at the HIV-1 Trans-Activation Responsive Element (TAR)

Early after HIV infection, proviral transcripts are alternatively spliced and completely processed into mRNAs that are translated to Tat and Rev regulatory proteins and Nef [9]. Tat RNA binding protein has particular specificity for the nascent TAR RNA structure (nts +1 to 57) [10]. Tat/TAR interaction stimulates the epigenetic modification of the TSS, the release of RNAPII from pausing and the rate of new initiation at the HIV promoter [11]. Rev is an RNA binding protein with specific affinity for the Rev-responsive element (RRE) and also, the 5′-UTR (stem loop (SL) 1) [12]. Among its activities, Rev/RRE complex mediates the assembly of RNPs for nuclear export by the CRM1 nuclear export receptor and retains unspliced and singly spliced (US, SS) HIV transcripts in appropriate stoichiometry [11,13]. Despite CRM1 nuclear export activity is normally reserved for noncoding snRNAs and host proteins, the Rev/RRE-dependent US and SS mRNAs are licensed for translation. Just as important for HIV proliferation is that a small portion of US transcripts become dimerized and packaged into virions. Steps to reaching consensus on this virus-host interface are a goal molecular virologists [14].

2.2. HIV RNA Structures Formed by Heterogeneous 5′UTR nt-nt Pairings

Composed of heterogeneous structural motifs, the HIV 5′-UTR coordinates transcription, splicing, translation and packaging and also engenders the hallmark early replication events: reverse transcription and integration [4,5]. Within the 5′-terminal ~350 nucleotides (nt) of the precursor RNA, the RNA elements are the TAR stem-loop, metastable PolyA hairpin, unique (U5) region and segment containing tRNA primer binding site (PBS), splicing donor (SD), dimerization initiation site (DIS), core encapsidation signal (CES) and AUG
start codon (Figure 1A). Mutations in the 5′-UTR have a direct impact on translation and packaging, but alter the overall folding of the RNA, thus complicating the dissection of either process [13,15].

RNA folding experiments with segments of the 5′-UTR have demonstrated biophysical equilibrium between nt–nt pairings fosters two predominant conformers that are monomeric and dimer-competent. By the analysis of nt–nt pairings that promote the intramolecular stability of either monomer or dimer-competent conformations in biochemical, biophysical and genetic experiments, consensus has been reached of structural motifs affecting viral replication events [16]. In the dimer-competent conformation, long range pairing of U5 with residues around the translation start codon exposes DIS for intermolecular dimerization (Figure 1B). Residues spanning the 5′-SD sequester in a three-way junction likely to preclude U1snRNP recognition and forestall alternative splicing. In the monomer conformation, U5 pairs with DIS, precluding intermolecular dimerization. Tertiary modeling from these experimental input constraints predicted metastable nt–nt pairings at the bottom of PolyA hairpin. For instance, U103C reduced the competitive packaging activity of the mutant RNA [17] and increased the translation rate [18], indicating that thermodynamic equilibrium can significantly influence the utility of the anomalous HIV RNA. Additional in-solution studies validated the U103C function change was attributable to altered host binding protein [19,20].

### 2.3. Co-Transcriptional Pause Is Coupled with the Covalent Modification of TSS and CBC Engagement

Just after RNAPII initiates host gene transcription, the C-terminal domain (CTD) is phosphorylated at serine5 (Ser5) and the DRB sensitivity-inducing factor (DSIF) recruits the negative elongation factor complex (NELF) onto the chromatin [21–23]. The four-component NELF complex induces promoter-proximal pausing ~20–50 bases downstream of the TSS. The RNAPII Ser5-phosphorylated CTD and DSIF Spt5 subunit recruit the mammalian capping enzyme (CE) to the transcription start site (TSS) [24,25]. While still
tethered to the CTD, the CE catalyzes the covalent attachment of a non-templated guanosine to the TSS of RNAPII nascent RNAs [26], as summarized in Figure 2.

**Figure 2.** Precursor RNA fate is determined through the co-transcriptional recruitment of RNA binding proteins and subsequent rearrangement of RNP (ribonucleoprotein) components. Nascent RNA shown with paused RNA polymerase II, Blue. CE, capping enzyme. * CRM1 chaperone activity.
Blue shape with black wavy line, RNA polymerase II paused on chromatin. NELF, negative elongation factor; CE, capping enzyme; pTEFb, positive transcription elongation factor b; NPC, nuclear pore complex. (A) Precursors of mRNA templates are completely spliced and licensed for nuclear export and CBP80/CBP20 nuclear cap-binding complex (CBC) exchange to eIF4E for canonical cap-dependent steady state translation. (B,C) snRNA and snoRNA gene products engage distinct RNA fate pathways that culminate in nucleolar trafficking and assembly into spliceosomes and ribosome. (D) Early HIV precursors become completely spliced mRNA templates by removal of alternative introns (dashed lines) that are licensed for the mRNA transport receptor NXF1/NXT1 and CBC exchange to eIF4E. These mRNAs form polysomes that translated Tat, Rev, Nef. (E) Late HIV precursors experience binding of Tat to TAR that trans-activates co-transcriptional capping and pTEFb activity. Rev binding to RRE activity results in 5′-cap hypermethylation, CRM1 nuclear export and specialized translation unaffected by mTOR. These mRNAs form polysomes that translated viral accessory and structural proteins. (F) The dashed line indicates a minority of unspliced RNA is bound by myristoylated (Myr, mauve bars) Gag polyprotein (mauve circles) and experienced dimerization at the plasma membrane. The dimeric RNA serves as genomic RNP that packaged into progeny virions.

The guanosine cap is appended by a uniquely stable 5′-5′ linkage (Figure 3A). The CE catalyzes methylation at the N7 position of guanosine to form the m7G-cap, which is immediately bound by heterodimeric CBP20-CBP80, forming the nuclear cap-binding complex (CBC) [27,28]. Capping of the TSS is a three-step process by CE: (1) Removal of the 5′-gamma phosphate and (2) Addition of non-templated guanosine in a distinct 5′-5′ pyrophosphate linkage [29]; (3) Methylation of the non-templated guanylate by the RNMT methyltransferase domain using the methyl donor S-adenosyl methionine [30–33].

![Figure 3. Structural basis for 7-methylguanosine (m7G) base recognition by cap-binding proteins.](image)

(A) Transcription start site of nascent RNAPII transcripts experience 5′-5′ linkage to guanosine that is methylated at the N7 position to form the m7G-cap. (B) Space-filling models present the conserved m7G-cap binding pockets of: CBP20 of the CBP20/CBP80 heterodimer; cytoplasmic cap binding protein, eIF4E; trimethylguanosine synthase, TGS1; poly(A)-specific ribonuclease, PARN.

Within CBC, the CBP20 RNA recognition motif (RRM) sandwiches the m7G-cap between two aromatic residues (Figure 3B). The aromates engage the m7G in pi-pi cation-πi stacking interactions that stabilize the 5′-end of the nascent RNA prior to the release of the paused polymerase. That CBC-m7G-cap stimulates the subsequent formation of pre-initiation complexes at the promoter suggested synergy between the post-transcriptional RNPs and transcriptional initiation events back at the promoter [34].

Recruitment of the positive transcription elongation factor (p-TEFb) and its phosphorylation of Ser2 of CTD [35], DSIF [36,37] and NELF [38] activates the completion of the transcription cycle [24,39,40]. Cycles of CTD phosphorylation and dephosphorylation accompany the extension of the RNA precursors and modulate transcription speed [40]. Exchanges of proteins from RNAPII to the CBC-bound mRNA are reactions measured on the order of a few seconds that modulate the intramolecular refolding of RNA structures, termination of transcription and 3′-end processing [41–44]. Whereas, CBC of mRNA precursors transition to CBC-REF/ALY, sn/snoRNA precursors transition to CBC-ARS and CBC-PHAX (Figure 2) [30,31,45–50]. Even before the completion of the transcription cycle, rearrangements of RNP components accompany RNA-fate decisions.
2.4. CBC-m7G Precursor mRNAs Assemble Export-Competent RNPs

The CBC influences the pattern of alternative splicing by stabilizing snRNP-splice site interactions with substrate RNA [39]. CBC stabilizes the recognition of the 5’-proximal splice site by U1 snRNP, followed by the U4/U6-U5 tri-snRNP [51–54]. Thereafter, CBC-associates with REF/ALY, which transfers onto exon-exon junctions and an 3’-end processing completes the assembly of export-competent RNPs [51–53] (Figure 2A).

REF/ALY deposition on exon-exon junctions facilitates joining with the NXF1/NXT1 (TAP/p15) nuclear export receptor and nuclear export of CBC-bound mRNA through the nuclear pore complex (NPC) (Figure 2). In the cytosol, the m7G-cap experiences the exchange of CBC to eIF4E, which has a similar binding motif and engages m7G in an aromatic sandwich domain (Figure 3B). The exchange of CBC for eIF4E is a principal requirement for global cap-dependent translation (more below).

2.5. Co-Transcriptional Capping of HIV RNA Is Stimulated by Tat/TAR

HIV Tat/TAR-dependent phosphorylation of RNAP II CTD is crucial not only in promoting transcription elongation, but also in stimulating nascent viral RNA capping [55]. Phosphorylation of CTD by Tat-induced p-TEFb enhances the CE-guanylyltransferase activity and transcription elongation [55]. There is physical interaction between the CE and the C-terminal domain of Tat bound to TAR [56,57]. Whether or not the co-transcriptional stimulation of guanylyltransferase and triphosphatase activities activated by Tat/TAR influences the fate of viral transcripts remains to be fully investigated.

2.6. Studies Have Ascertained the Importance of HIV Cap-Proximal 2′-O Ribose Methylation to Evade Host Detection

The TSS (+1) and second transcribed nt (+2) of many mRNA precursors and some snRNA precursors experience 2′-O-ribose methylation [58–61]. Catalyzed by cap methyltransferases (CMTR), CMTR1 is recruited early in transcription to Ser5-phosphorylated Pol II CTD, as reviewed in [34]. These RNA modifications to host mRNAs deflect sensing by RIG-I and other antiviral RNA sensors and are considered identifiers of transcripts as ‘self’, instead of inducers of innate immune suppression [28].

The cap-specific adenosine methyltransferase phosphorylated CTD-interacting factor 1 (PCIF1) catalyzes methylation of the cap-proximal adenosine to m7Gpppm6A on host mRNAs involved in transcriptional regulation and stress response [62,63]. Moreover, PCIF1-m6A methylation has been shown to attenuate interferon-β-mediated suppression of viral infection. Mutation or knockout of PCIF1 suppresses vesicular stomatitis virus (VSV) and rabies virus (RABV) infection [64]. VSV and RABV mRNAs are substrates of PCIF1, indicating PCIF1 activity contributes to viral evasion of innate immune suppression. PCIF1 methylation activity on host substrates was found to restrict HIV replication [63]. Analysis of the HIV-1 TSS initially identified guanosine-guanosine as the primary sequence at the 5′ end of HIV-1 in lymphocytes [65–67]. Recently, an adenosine at the HIV TSS was detected infrequently [68]. Thus, PCIF1 improbably contributes to HIV evasion of innate immune suppression directly [69]. HIV accessory viral protein R (Vpr) has been shown to counter PCIF1 repression of proviruses by triggering its ubiquitination and degradation through a proteasome pathway [63]. Genome-wide screens of PCIF1-knockout cells identified several transcription factors, e.g., ETS1 and HUSH family components. PCIF1 activity on ETS1 mRNA was shown to stabilize the transcript, upregulating the ETS1 protein that repressed HIV promoter activity [69]. Vpr also counteracted transcriptional repression of proviruses by the HUSH complex that may also be regulated by PCIF1 [69]. Experiments are warranted to fully investigate PCIF1 activity on HUSH components and other HIV host dependency and restriction factors [63].
3. CBC Exchange Is a Precursor to Global Cap-Dependent Translation

3.1. eIF4E Binding to m⁷G-Cap Is Necessary for Global mRNA Translation

Cell proliferation and cell cycle progression are modulated by fluctuations in the eIF4E-dependent translational pathway [70, 71]. Global control of eIF4E-dependent translation is finely tuned through the evolutionarily conserved serine/threonine kinase, mechanistic target of rapamycin (mTOR) [72]. Amongst the substrates of mTOR are the eIF4E binding proteins (4EBPs). Inhibition of mTOR upregulates hypo-phosphorylated 4EBPs (hypo-4EBPs). These proteins serve as allosteric inhibitors of eIF4E-bound to m⁷G-cap mRNA and block interaction with eIF4G, forestalling eIF4E interactions to form the trimeric eIF4F mRNP (Figure 4).

The eIF4F complex is composed of eIF4E cap-binding protein, eIF4G scaffold protein, and eIF4A helicase, as reviewed in [73]. Hypo-4EBPs promptly downregulate eIF4F translation initiation on a global scale [71] (Figure 4). Hypo-4EBPs are activated by nutrient deprivation, viral infections, reactive oxygen species (ROS) and other stressors [74]. Allosteric inhibition of eIF4E by hypo-4EBPs is a trigger for cell cycle progression from G1/S phase to the G2/M phase [75]. The recovery of hyper-phosphorylated 4EBPs (hyper-4EBPs) by activated mTOR stimulates the progression of the cell cycle from mitosis to G1 phase by liberating eIF4E to nucleate the trimeric eIF4F complex [76]. eIF4G interaction with eIF3 triggers binding of the small ribosomal subunit with the eIF2.GTP.tRNA<sub>i</sub><sup>MET</sup> ternary complex, eIF1/1A and eIF5 for ribosome scanning and AUG recognition, 60S ternary complex, eIF1/1A and eIF5 for ribosome scanning and AUG recognition, and eIF4F triggers binding of the small ribosomal subunit with the eIF2.GTP.tRNA<sub>i</sub><sup>MET</sup> ternary complex.
complex, eIF1/1A and eIF5 for ribosome scanning and AUG recognition, 60S joining and polypeptide elongation.

The global footprint of eIF4F activating cell growth underlies its frequent hyper-regulation in malignancy and its antagonism by successful pathogens [76]. Functional genomics analyses have documented reprogramming of the eIF4F-dependent translatome is a hallmark of neoplasms [76]. Causes have been attributed to mutational inactivation of 4E BP, constitutive signaling by mTOR and dysfunction of eIF4E and eIF4G homologs [77]. Stimuli that dysregulate 4E BP perturb cellular homeostasis on a global scale. Such perturbation of eIF4E-dependent translation attributable to Vpr in HIV—associated malignancy will be important to investigate in future studies.

3.2. eIF4E-like Proteins Substituting for eIF4E Activate Translation Unaffected by mTOR

An adaptive translation response to stressors was recently attributed to an independent protein family of m7G-cap binding protein, eIF4E3 [78]. Vertebrate eIF4E3 is not an isoform of eIF4E and instead represents an independent family of cap-binding protein [79]. Vertebrate eIF4E3 shares 25% sequence identity with vertebrate eIF4E family members (eIF4E-1, -2) and exhibits differences in the cap-binding pocket that convey activity trans-dominant to eIF4E [80]. Like CBC, eIF4E sandwiches m7G-cap between two aromatic residues. Elegant mutagenesis experiments characterized the atypical mode eIF4E3 sandwiching the 5′-cap with one tryptophan (Trp) and a cysteine (Cys) residue [80]. The eIF4E and eIF4E3 binding affinity for methylated guanosine-cap is 1000-fold greater than to guanosine [80,81].

During physiological downregulation of eIF4E, eIF4E3 engages the eIF4G scaffold protein for recruitment of eIF3. Two studies of eIF4E3 mutation or elimination have identified tumor suppressor activity attributable to the Trp/Cys cap-binding contacts [80,82]. Pertinent to virologists, physiological or drug-induced mTOR inhibition downregulates eIF4E, but does not necessarily eliminate cap-dependent translation because of initiation RNPs composed of eIF4E-like cap-binding proteins, e.g., eIF4E3, and the alternative, cap-independent initiation (more below).

3.3. Alternative RNA-Protein Interactions Support Cap-Dependent Translation

Growing literature documents additional protein families [83–91] can tether the 43S ribosomes for scanning to AUG start codons (reviewed in Borden et al.) [92]. The middle domain of eIF4G conveys the interaction with eIF3-bound to the 43S ribosomal subunit-eIF2.GTP.tRNAiMET ternary complex, eIF1/1A, eIF5. Some adaptor proteins have a middle domain like eIF4G (MIF4G-like domain) [93,94] that tether eIF3 complexes to mRNA templates [95]. DAP/p97 is a MIF4G-like protein that has been shown to tether eIF3-complexes for cap-dependent translation without eIF4E. In quiescent cells, the poly(A)-specific ribonuclease (PARN) provides the m7G-cap binding protein and DAP/p97 tethers the eIF3-ribosome without eIF4G [87,90]. Another RNP for cap-dependent translation during physiological mTOR inhibition and eIF4E depletion is DAP5-eIF3d, which may function interchangeably with eIF4E-eIF4GI on selected mRNAs [90]. Moreover, direct binding of eIF3d to m7G-cap has been shown to tether ribosomal subunits for scanning of c-jun mRNA [91].

The MIF4G domain-containing protein, CTIF, has been shown to be unique in directing translation of CBC-capped mRNAs that have yet to exchange CBC for eIF4E, including the replication-dependent histone mRNAs [96,97]. Recently, CTIF has been shown to tether CBC-bound mRNPs to the perinuclear region of the nuclear pore through the nucleoporin-binding protein DDX19B [98]. The perinuclear retention of CTIF by DDX19B repressed translation of CTIF-CBC mRNPs. Notably, CTIF-CBC mRNPs released to the cytoplasm were shown to form eIF4E-independent polysomes, demonstrating the translatability of CBC-bounded mRNAs. The CTIF-DDX19B interaction was shown to play an inhibitory role in nonsense mediated decay [98–100]. CTIF is an inhibitor of HIV Gag synthesis [99], which may also be attributable to perinuclear trapping [98].
3.4. Alternative RNA-Protein Interactions Support Cap-Independent Internal Ribosome Entry

Ribosome recruitment to mRNAs under conditions eIF4E is downregulated also may be attributable to internal ribosome entry site (IRES) [101,102]. Indeed, in viruses that lack m7G-cap, e.g., picornaviruses, internal ribosome entry and translation initiation without ribosome scanning were shown to be absolutely required for viral protein synthesis [103,104]. The IRES of naturally uncapped picornavirus RNAs were the first shown to tether the ribosome in proximity to the start codon for translation initiation without ribosome scanning (encephalomyocarditis virus, poliovirus) [103,104]. The significance of IRES activity in hosts, and therefore translation initiation without ribosome scanning, was shown to belong to post-transcriptional gene networks that carry out cell death and survival decisions [103,105]. The global scope of IRES activity relative to eIF4E3 and other widespread forms of translation initiation involving ribosome scanning remains to be completely quantified in hosts. The list of exceptional RNPs for ribosome recruitment during physiological downregulation of eIF4E has been growing [92].

The case for translation initiation by both linear and discontinuous ribosome scanning of select HIV RNA has been documented, e.g., bicistronic HIV env [106,107]. Notably, the cap-dependent recruitment of ribosomes and scanning to the AUG start codon is a fundamentally distinct process from the cap-independent process of internal ribosome entry to engage the start codon [103,104,108,109]. There is compelling evidence supporting the presence of an IRES within HIV tat 5′-UTR [110]. HIV IRES activity provides a cap-independent explanation for viral protein translation that is responsive to arrest of the cell cycle and other conditions downregulating eIF4E [110–119]. Elegant study of unspliced HIV RNA has identified a conditional IRES activity in the 5′-UTR that is negatively regulated and becomes de-repressed by oxidative stress [120]. The extensive study of cap-independent ribosome entry to engage the start codon of HIV mRNAs and the activity of IRES trans-acting factors are topics of recent authoritative reviews, e.g., [121–124].

4. Unique RNP Assembly Pathways Drive the Post-Transcriptional Fates of TMG-Capped sn/snoRNAs and Anomalous HIV RNAs

4.1. CRM1-Dependent Nuclear Export of CBC Bound m7G-snRNA Leads to Cap Hypermethylation, Retrograde Transport and Nucleolar Trafficking

The scaffolding function of CBC on snRNA precursors underlies its’ dynamic progression to CBC-NELF to CBC-ARS2 and to CBC-phosphorylated nuclear export adapter (PHAX) (Figure 2B). PHAX tethers the snRNA cargo to the CRM1 nuclear export receptor. PHAX de-phosphorylation in the cytosol releases CRM1 from the snRNA cargo and CRM1 serves to recycle CBC through an interaction of Importin-β with the CBP80 subunit of CBC [125].

The TGS1-bound m7G-cap undergoes separate and distributive reactions that transfer methyl groups to the guanine N2 position from the methyl donor S-adenosyl-L-methionine (SAM/AdoMet) [126]. TGS1 catalysis produces two S-adenosyl-L-homocysteine (AdoHcy) molecules and the N2,2,7-methyl guanosine cap (TMG-cap) (Figure 5A). TGS1 affinity for the snRNA m7G-cap was conveyed by the aromatic amino acid sandwich motif, whereas TMG-cap is incompatible. To date, the only solved vertebrate protein structure that is compatible with the TMG-cap structure is Snurportin1 [127]. Snurportin1, also known as the snRNP-specific import adaptor, binds TMG-cap through aromatic rings of Try and base stacking by guanine of the snRNA strand (Figure 5B).

The Snurportin1-TMG-capped snRNA complex binds the Importin-β receptor for retrograde transport of the processed snRNA [128,129]. Thereafter, CRM1 promotes release and nuclear export of Snurportin1. The TMG-capped snRNP traffics through nucleoli and guides the 2′-O-methylation or pseudouridylation of snRNA and rRNA, which is critically important for the assembly of spliceosomal and ribosomal RNPs [130].
Viruses, 2022, 14, 935

Figure 5. The hypermethylation of the m^7G-cap eliminates capacity for Watson-Crick base pairing and for CBC/eIF4E/TGS1 binding. (A) The 2,2,7-trimethylguanosine (TMG-cap) appended to the 5'-terminus of RNA. (B) Space-filling model of the TMG-binding pocket of Snurportin1 and NCBP3 modeled on the structure of PARN. In each, the TMG-cap exhibits base stacking with the aromatic ring of tryptophan (W) in the polypeptide and guanine in the cognate RNA.

4.2. snoRNA m^7G-Cap Experiences Hypermethylation in the Nucleus Prior to Nucleolar Trafficking

Whereas snRNA-caps undergo hypermethylation in the cytosol, snoRNA-caps experience TGS1 activity in the nucleoplasm [131,132]. Following completion of the transcription cycle and CBC binding by PHAX, snoRNA traffic to nuclear Cajal bodies and CBC exchanges to TGS1 for cap-hypermethylation [133] (Figure 2C). Again, CRM1 is involved, but instead of nuclear transport activity, CRM1 provides chaperone activity for the exposure of Nop58 nucleolar localization sequence (NoLS) [134]. The covalent modification of CRM1 by leptomycin B was shown to trap TGS1 with snoRNPs and preclude nucleolar transport [11,135]. The nucleolar TMG-capped U3 snoRNA function in ribosome assembly and involve U4/U6-U5 snoRNP and U1 snRNP [136,137]. In sum, TGS1 activity on snoRNA and snoRNA requires disparate interaction with CBC-PHAX and CRM1. The unique pathways for retrograde transport of snRNAs and the nuclear retention of snoRNA culminate in the mutual assembly into nucleolar RNP s that have cooperative activity on the fate of mRNAs.

4.3. HIV Infectivity Is Diminished by Downregulation of HIV TMG-Cap

TGS1 and Rev were identified as binding partners in yeast two hybrid screens, and co-precipitation studies demonstrated HIV Rev/RRE-dependent mRNAs are substrates of TGS1 in the nucleus [138]. Exogenous expression of TGS1 was shown to increase expression of the Rev/RRE-dependent viral US RNA significantly and this activity was abrogated upon replacement of Rev/RRE by the constitutive transport element (CTE). Reinforcing the importance of TGS1-Rev interaction, TMG-cap is enriched in HIV US and SS mRNAs, but not MS HIV RNAs (Figure 2D–F). The downregulation of TGS1 has been shown to abolish TMG-cap from US/SS viral RNAs, eliminate specialized translation of viral proteins, and diminish the infectivity of normalized virions by several orders of magnitude [20]. TGS1 and the host factors supporting the activity of the HIV TMG-cap are crucial host dependency factors that warrant further investigation [20].

4.4. Selected Host and Viral mRNAs Are Substrates for Specialized Translation and TGS1

JunD is among the host mRNAs that exhibit specialized translation [139]. JunD is a component of the heterodimeric AP1 transcription factor, e.g., JunD/Fos, whose DNA binding activity is triggered by oxidative stress and enables cells to cope with ROS and restore homeostasis [140]. In response to oxidative stress, selenoproteins involved in antioxidant defense exhibit select upregulation of translation (Gpx1, Gpx4, TR1, SelS, SelK and Sps2) [141]. Selenoproteins serve as oxidative stress reducers, anti-inflammatory actors and facilitators of wound healing [142]. Selenoprotein translation is needed in cells to cope with oxidative stress and re-balance ROS/scavenger equilibrium [142]. Wurth et al. captured TMG-capped selenoprotein mRNAs using TMG-specific antisera in sensitive RNA immunoprecipitation and microarray experiments [143]. RT-qPCR
and TGS1 siRNA downregulation validated TMG-capped selenoprotein mRNA were substrates of TGS1. Moreover, the selenoprotein, Gpx1, was shown to require TMG to support efficient translation. Experiments are warranted to validate Gpx1 is a substrate for the specialized translation pathway used for JunD and HIV protein synthesis. A very recent study has shown the selenoproteome to be altered slightly by HIV infection [144] and the significance to HIV/AIDS warrants investigation.

Selenium is an essential micronutrient incorporated into selenocysteine for selenoprotein translation [145]. Clinically, selenium supplementation is protective to people living with HIV (PLWH) [146]. Both HIV and selenium deficiency cause CD+ T cell chronic activation and proliferation that culminates in T cell exhaustion and apoptosis and the combination may exacerbate T cell decline [147]. Meta-analysis of HIV infected patients posited selenium was required for selenoprotein translation and delayed the onset of immune cell depletion [148]. Selenium deficiency in untreated HIV-infected patients was associated with a lower CD4 T-cell count [149].

5. TGS1 Is Tethered to HIV-1 Rev/RRE-Dependent RNAs by Host Nuclear RNA Helicase

5.1. Nuclear RNA Helicase Supports Recruitment of TGS1 to HIV RNA and Cap Hypermethylation Licenses Specialized Translation Unaffected by mTOR

Investigation has begun to fully explain why the abrogation of TMG-cap significantly diminishes HIV-1 proliferation [20]. The HIV TMG-cap was shown to assemble CBP80/NCBP3 polysomes that initiate structural/accessory protein synthesis unaffected by mTOR [20]. To engage TGS1, HIV 5′-UTR requires the binding of nuclear DHX9/RNA helicase ADHX9 (RHA) (Figure 2E). RHA is the host dependency factor of HIV that also stimulates translation of other retroviral and select host mRNAs through its recognition of the structure of the post-transcriptional element (PCE) in these 5′-UTRs [150–156]. HIV 5′-UTR was identified to contain PCE that is recognized by RHA to facilitate polyribosome association and stimulate cap-dependent translation [157,158]. RHA-RNA co-precipitation and PCE reporter assays identified HIV TAR-PolyA regions and the three-way junction structure of the PBS-segment within the 5′-UTR were necessary for PCE activity [158,159].

Homology modeling of RHA based on crystal structure of Drosophila Maleness (MLE) protein suggested that the RNA binding interface in the conserved double-stranded RNA binding domain (dsRBD) II is likely partially sequestered by the helicase core domain and thus, the dsRBD I was implicated with the major role in target RNA recognition [160]. Nuclear magnetic resonance and isothermal calorimetry data showed RHA’s dsRBD I interacts with double-stranded residues at the base of the PBS-segment [160,161]. Structural analysis of RHA dsRBD I association with PBS-segment identified shape-specific recognition at the three-way junction of the primer activation stem, tRNA-like element stem and tRNA annealing stem [160]. The shape-specific recognition by RHA is abrogated by a single A140C structural mutation that results in an elongated PBS-segment [160,161].

RHA-PCE interaction has been identified to tether TGS1 to the HIV RNA for hypermethylation of the m7G cap [20]. The downregulation of RHA or A140C structural mutation of PCE eliminates the hypermethylated-cap from the Rev/RRE-dependent transcripts [20]. Without TMG-cap, eIF4E-dependent translation mRNPs assembled and were downregulated by mTOR inhibition. The TMG-cap licenses viral mRNAs for specialized translation unaffected by mTOR.

5.2. Bimodal Translation Control Is Significant to Persistent Infection

HIV structural protein translation continues during G2/M arrest and other conditions eIF4E-mediated translation is inhibited [75,117]. By emulating the TMG-cap ascribed to the noncoding sn/snoRNA, TMG cap licenses the Rev/RRE-dependent mRNA for cap-dependent ribosome recruitment and scanning supported by an unprecedented collection of nuclear proteins in the CBP80/NCBP3-RHA RNP [20,139]. Evidence for the function of NCBP3 in complex with CBP80 has been provided [139] and homology modeling of NCBP3 was built due to its sequence similarity with PARN [162]. PARN is a 3′-UTR binding protein
with binding specificity for polyadenylate residues and transient interaction with m\(^7\)G-cap that results in exonucleolytic decay. The cap binding pocket in NCBP3 is more open than that of PARN, leaving enough space for the two methyl groups at N\(^2\) of the guanosine in the TMG-cap (Figure 5B). Similar to Snurportin1, NCBP3 has an aromatic amino acid (Trp) to support the stacking of TMG-cap, as well as an open space to accommodate additional stacking of the adjacent purine of TMG-cap in the RNA (Figure 5B). The interaction of NCBP3 with TMG-cap is speculated to be stabilized by guanine at the HIV TSS, thus mimicking the guanne stabilization of snRNA TMG-cap with Snurportin1. The details of these molecular interactions require further structural studies.

As discussed, the translation of MS mRNA is dependent on eIF4E and halted by mTOR inhibition (Figure 6, left panel), whereas the specialized translation pathway of the Rev/RRE-dependent mRNAs is unaffected by mTOR (Figure 6, right panel). Productive HIV replication in lymphocytes has been shown to downregulate eIF4E in a manner similar to mTOR inhibition [20,75]. The HIV accessory protein Vpr was shown sufficient to upregulate hypo-4EBP (Figure 6, arrow) [75], which halts the de novo synthesis of Tat and Rev [20]. Pre-existing HIV TMG-capped mRNAs in CBP80/NCBP3 mRNPs maintain specialized translation [20].

**Figure 6.** The HIV early and late mRNAs engage independent translation pathways that interdependently control the expression of viral regulatory proteins and structural/accessory proteins. (Left) HIV early mRNAs are fully processed mRNAs that undergo canonical eIF4E-dependent translation to Tat, Rev and Nef. Hypo-phosphorylated (hypo) 4E-BP allosterically binds eIF4E and blocks eIF4G interaction and halts the translation initiation. (Right) Trimethylguanosine (TMG)-cap of the Rev/Rev-responsive element (RRE)-dependent mRNAs licenses specialized translation independently of eIF4E activity. HIV unspliced and singly spliced (US and SS) mRNAs engage Rev at the RRE (gray protein binding gray RNA element) and subvert canonical CBC exchange to eIF4E and engages CBP80/NCBP3 Vpr upregulates hypo-4E-BP [75] and inhibits eIF4E-dependent translation of host proteins and Tat, Rev, Nef. The specialized translation of the Rev/RRE-dependent TMG-capped mRNAs endures until lack of Tat/Rev activity curtails biosynthesis of the US/SS RNA [20]. The downregulation of the TMG-capped mRNAs encoding viral accessory/structural protein and attenuates virus proliferation [20].

Molecular clones that abolish TMG-cap experience mono-modal translation dependent on eIF4E and replicate poorly [20], suggesting the bimodal translation control conferred by CBP80/NCBP3 was beneficial for maintaining infected cells [20]. The CBP80/NCBP3 RNPs manifest a host mechanism that bypasses mTOR inhibition for translation of host stress response proteins [136]. The co-opt of specialized translation by HIV maintains translation of virion proteins despite mTOR inhibition [20,117]. Viral activation of hypo-4EBP through
Vpr, uncouples the precursor–product relationship between Tat and Rev and the US/SS mRNAs and serves to attenuate virus proliferation [20].

5.3. Unexpected Findings from Study of HIV Unspliced RNA by In Situ Hybridization-Proximity Ligation Assay Protocol (ISH-PLA)

Studies have documented HIV Rev/RRE-dependent translation mRNPs exclude eIF4E [20,75,100]. Consensus for the preferential association of the polysomal HIV US mRNA with CBP80 developed through immunoprecipitation studies and visualization by ISH-PLA [18,73,84]. Consistent with preferential association of CBP80 with the unspliced RNA, the overexpression of CBP80 increased Renilla synthesis from chimeric gag-renilla US RNA [100]. The change was due to an increase in both cytoplasmic accumulation and translation of the US mRNA, suggesting a dearth of endogenous CBP80 had been rescued.

Results with the ISH-PLA protocol resonated with prior observations that Rev/RRE interaction bolstered nuclear export and the translation of HIV unspliced RNA [163,164]. ISH-PLA detected HIV US RNA in the cytosol of Rev-deficient cells [100] attributed to a minority RNP that was unique from the CBP80 translation RNP [165]. It will be interesting to ascertain whether TMG-capped RNA is a component of the minority RNP in Rev-deficient cells.

Identifying RNP components that license a minority HIV RNP, could inform the long-standing issue authentic HIV RNA in productively infected lymphocytes exists in mutually exclusive RNPs directed to translation and packaging [166]. Studies of productively infected lymphocytes have documented HIV genomic RNA packaged into virions does not require prior experience as template for Gag translation, and thus may represent a distinct RNP [167]. Rev-deficient, but CTE-containing US RNAs lack TMG-cap [138] and therefore lack specialized translation, yet exhibit efficient encapsidation [168]. Experiments are warranted to validate HIV TMG-capped US RNA is poorly packaged into virions.

In summary, it is now well-established that HIV MS RNPs carry out the maturation steps engaged by host protein-coding mRNPs (Figure 2A,D). However, HIV precursor RNAs undergoing the co-transcriptional trans-activation by Tat/TAR interaction and Rev/RRE-dependent maturation take on properties of host non-coding RNAs (Figure 2E). They experience hypermethylation of m^7G-cap (Figure 2B,C), assemble RNPs that transit nucleoli [169,170] and experience CRM1-dependent nuclear export. In departure from the noncoding RNAs, the TMG-capped Rev/RRE-dependent mRNAs also experience specialized translation through an initiation pathway in common with host JunD, an AP1 transcription factor [139]. JunD activity during oxidative stress helps cells to rescue redox homeostasis [140].

Redox homeostasis has been a pillar in the construction of HIV Cure strategies to manipulate latently infected cells in aviremic patients [171–173]. Oxidative stress has been proposed to send proviruses into deep latency [173]. Until the identification of the CBP80/NCPB3-specialized translation pathway that is licensed by TMG-cap on selected mRNAs [20,139], host translation during oxidative stress was attributed largely to cap-independent initiation [143]. The recent data suggest hosts utilize specialized translation to deal with oxidative stress. It is possible that HIV co-opt of host specialized translation enables viral persistence concomitant with an effective host response to stress.

6. Issues, Experimental Questions, Closing

6.1. TMG-Cap Expands the Conformation Space of the HIV-1 5′-UTR

While investigating HIV 5′-UTR determinants for competitive packaging, Ding et al. reported that the base pairing between m^7G-cap and cytosine (C) 57 is an important determinant (Figure 1B) [19]. They also reported TSS heterogeneity disrupts the m^7G-C57 pairing and postulated the unpaired m^7G-cap was available to engage eIF4E for translation [19]. Isolation of HIV US RNA from virions or polysomal mRNPs was performed and TSS heterogeneity was identified. The 5′-end of virion RNA was inferred m^7G-cap-G, while polysomal mRNA was inferred m^7G-cap-GGG.
Using experimentally determined 5′-UTR input constraints and 30 million iterative Monte Carlo Simulations, tertiary (3D) models have been predicted on the simRNA platform [174]. Molecular dynamic visualization of the conformational differences between Cap-G and Cap-GGG were reviewed. Consistent with Ding et al. [19] Cap-G was sequestered at the confluence of TAR, PolyA and U5 helices (Figure 7A). In 3D, TAR-PolyA-U5 junction was compact and 5′-G and C57 were the Watson–Crick pair at the end of TAR. In addition, C58-G104 basepaired, constricting the 5′-G at the confluence of TAR-PolyA-U5 (Figure 7A and Video S1). With the addition of guanine residues at the TSS (Cap-GGG), significant structural change was apparent at the central hub of TAR-PolyA-U5 (Figure 7B and Video S1). Notably, the Cap was separated from the junction of PolyA-U5. The net result was the junction looks strong, rigid and well defined and Cap was unpaired for cofactor interaction. Consistent with this model, an HIV TMG-cap is incompatible with base pairing since hypermethylation of m7G-cap disrupts the Watson–Crick interface, however TMG is unsuitable for eIF4E interaction [80,81]. As discussed above, cell-based experiments have documented HIV TMG-cap engages NCBP3/CBP80 heterodimer for translation in a Rev/RRE-dependent manner [20]. Taken together, in-cellulo data, in-solution analyses and in silico modeling converge on the hypothesis that TSS heterogeneity modulates HIV translation control, as well as the short- and long-range interactions in the HIV 5′ UTR that regulate genome dimerization and packaging [68,175,176]. Future studies are warranted to document the TSS of the TMG-capped RNA. Ultimately, structural study of the CBP80/NCBP3 TMG-cap interface may provide new clues for therapeutic intervention of HIV proliferation.

![Figure 7. Predicted tertiary structure context of the HIV Cap of the HIV NL4-3 5′-UTR given transcription start site heterogeneity of one guanosine (G) or GGG. Zoom-in on the junction of TAR (magenta)-PolyA (blue)-U5 (green) helices. Cap, magenta atom; G104, blue atom and U105, green atom. (A) Cap-G at the 5′ terminus. (B) Cap-GGG at the 5′ terminus repositioned Cap ~26 Angstroms from the junction of PolyA-U5. Rotation of these structures is provided in Video S1.](image)

6.2. Closing

While constitutive specialized translation of HIV accessory proteins and virion proteins has been shown, the supply of US/SS mRNA templates is dictated by mTOR regulated translation of Tat and Rev [20]. Virological experiments have provided strong evidence virion proliferation is controlled by the bi-phasic cap-dependent translation (attributable to m7G and TMG-caps). As summarized in Figure 6, HIV Vpr-induced mTOR inhibition serves to attenuate the expression of viral regulatory proteins, which then downregulates the US/SS mRNAs encoding structural/accessory proteins. Experiments are warranted to measure the conservation of HIV specialized translation licensed by the TMG-cap in virus from patients and the closely related HIV-2.

Figure 7. Predicted tertiary structure context of the HIV Cap of the HIV NL4-3 5′-UTR given transcription start site heterogeneity of one guanosine (G) or GGG. Zoom-in on the junction of TAR (magenta)-PolyA (blue)-U5 (green) helices. Cap, magenta atom; G104, blue atom and U105, green atom. (A) Cap-G at the 5′ terminus. (B) Cap-GGG at the 5′ terminus repositioned Cap ~26 Angstroms from the junction of PolyA-U5. Rotation of these structures is provided in Video S1.

6.2. Closing

While constitutive specialized translation of HIV accessory proteins and virion proteins has been shown, the supply of US/SS mRNA templates is dictated by mTOR regulated translation of Tat and Rev [20]. Virological experiments have provided strong evidence virion proliferation is controlled by the bi-phasic cap-dependent translation (attributable to m7G and TMG-caps). As summarized in Figure 6, HIV Vpr-induced mTOR inhibition serves to attenuate the expression of viral regulatory proteins, which then downregulates the US/SS mRNAs encoding structural/accessory proteins. Experiments are warranted to measure the conservation of HIV specialized translation licensed by the TMG-cap in virus from patients and the closely related HIV-2.
Other questions include: Does TMG-cap contribute to masking HIV infection from innate sensing? Where is the recruitment of the NCBP3/CBP80 cap-binding complex taking place? Does the stimulation of co-transcriptional capping by Tat-bound to TAR alter the m^7G-CBC interaction to foster TGS1 activity, and what is the role of Rev or RRE in relation to TGS1 methyltransferase activity? Does TMG-cap interfere with U1 snRNP recruitment or otherwise subvert the splicing cycle, or contribute to any stage of CRM1 nuclear export or genomic RNA packaging. Does TMG-cap experience nucleolar trafficking in common with TMG-snoRNAs? What coordination, if any, is there in the nucleolar trafficking of TGS1 and Rev/RRE mRNPs, especially in light of the observation that HIV-1 Rev variants defective in nucleolar trafficking produce poorly infectious virions [170]. Molecular plasticity in the HIV RNA World is breaching the perceived distinctiveness between the RNP components that drive the fate of non-coding-RNAs and protein-coding RNAs.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v14050935/s1, Video S1. Anomalous HIV-1 RNA, how cap-methylation segregates viral transcripts by form and function. Rotations of the three-dimensional visualizations show differences in the orientation of the HIV-1 5′-Cap with the junction of the helical TAR, PolyA, U5 segments. Zoom-in taken from the model of the Dimer-prone 5′-UTR (356 nucleotides) [174] on the Cap site (magenta) near the junction of TAR (magenta); PolyA (blue); U5 (green). G104, blue atom and U105, green atom (Left) Cap-G. Cap appended to the transcription start site (Cap-G) was positioned close to the central hub of TAR-PolyA-U5 helices and engaged in Watson-Crick base pairing (G-C), as summarized in Figure 1; (Right) Cap-GGG. Cap is unpaired and separated from the junction of PolyA-U5 by ~26 Angstroms. For perspective, the widest measurement of the structure is 202 Angstrom.

Author Contributions: Conceptualization, K.B.-L.; writing—original draft preparation, K.B.-L.; writing—review and editing, K.B.-L., X.H., G.S., P.S.O. and S.S.; visualization, K.B.-L., D.Z., X.H., G.S. and P.S.O.; funding acquisition, K.B.-L. and X.H. All authors have read and agreed to the published version of the manuscript.

Funding: National Institutes of Health R01AI150460 to X.H. and K.B.-L. and the Hanlon and Schmidt Fellowship, College of Veterinary Medicine, University of Minnesota–Twin Cities to D.Z.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: Figures were created with BioRender.com.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design or the writing of the manuscript.

References
1. Coffin, J.M.; Hughes, S.H.; Varmus, H. Retroviruses; Cold Spring Harbor Laboratory Press: Plainview, NY, USA, 1997.
2. Leblanc, J.; Weil, J.; Beemon, K. Posttranscriptional regulation of retroviral gene expression: Primary RNA transcripts play three roles as pre-mRNA, mRNA and genomic RNA. *Wiley Interdiscip. Rev. RNA* 2013, 4, 567–580. [CrossRef]
3. Wu, J.; Xiao, J.; Zhang, Z.; Wang, X.; Hu, S.; Yu, J. Ribogenomics: The Science and Knowledge of RNA. *Genom. Proteom. Bioinform.* 2014, 12, 57–63. [CrossRef] [PubMed]
4. Berkhout, B. Structure and Function of the Human Immunodeficiency Virus Leader RNA. *Prog. Nucleic Acid Res. Mol. Biol.* 1996, 54, 1–34. [CrossRef]
5. Bieniasz, P.; Telesnitsky, A. Multiple, Switchable Protein: RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. *Annu. Rev. Virol.* 2018, 5, 165–183. [CrossRef]
6. Branlant, C.; Krol, A.; Ebel, J.; Lazar, E.; Haendler, B.; Jacob, M. U2 RNA shares a structural domain with U1, U4, and U5 RNAs. *EMBO J.* 1982, 1, 1259–1265. [CrossRef]
7. Liautard, J.-P.; Sri-Widada, J.; Brunel, C.; Jeanteur, P. Structural organization of ribonucleoproteins containing small nuclear RNAs from HeLa cells: Proteins interact closely with a similar structural domain of U1, U2, U4 and U5 small nuclear RNAs. *J. Mol. Biol.* 1982, 162, 623–643. [CrossRef]
8. Speckmann, W.A.; Terns, R.M.; Terns, M.P. The Box C/D motif directs snoRNA 5′-cap hypermethylation. *Nucleic Acids Res.* 2000, 28, 4467–4473. [CrossRef]
9. Emery, A.; Swanstrom, R. HIV-1: To Splice or Not to Splice, That Is the Question. *Viruses* 2021, 13, 181. [CrossRef]
10. Southgate, C.; Zapp, M.L.; Green, M.R. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. *Nature* 1990, 345, 640–642. [CrossRef]

11. Karn, J.; Stoltzfus, C.M. Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression. *Cold Spring Harb. Perspect. Med.* 2012, 2, a006916. [CrossRef]

12. Gallego, J.; Greetorex, J.; Zhang, H.; Yang, B.; Arunachalam, S.; Fang, J.; Seamons, J.; Lea, S.; Pomerantz, R.J.; Lever, A.M.L. Rev Binds Specifically to a Purine Loop in the SL1 Region of the HIV-1 Leader RNA. *J. Biol. Chem.* 2003, 278, 40385–40391. [CrossRef] [PubMed]

13. Singh, G.; Rife, B.D.; Seufzer, B.; Salemi, M.; Rendahl, A.; Boris-Lawrie, K. Identification of conserved, primary sequence motifs that direct retrovirus RNA fate. *Nucleic Acids Res.* 2018, 46, 7366–7378. [CrossRef] [PubMed]

14. Ivanov, D.; Kwak, Y.T.; Guo, J.; Gaynor, R.B. Domains in the SPT5 Protein That Modulate Its Transcriptional Regulatory Properties. *Mol. Cell.* 2010, 37, 739–750. [CrossRef]

15. van Bel, N.; Ghafari, A.; Das, A.T.; Berkhout, B. The HIV-1 leader RNA is exquisitely sensitive to structural changes. *Virology* 2015, 483, 236–252. [CrossRef]

16. Keane, S.C.; Summers, M.F. NMR Studies of the Structure and Function of the HIV-1 5′-Leader. *Viruses* 2016, 8, 338. [CrossRef]

17. Kharytonchyk, S.; Monti, S.; Smaldino, P.J.; Van, V.; Bolden, N.C.; Brown, J.D.; Russo, E.; Swanson, C.; Shuey, A.; Telesnitsky, A.; et al. Transcriptional start site heterogeneity modulates the structure and function of the HIV-1 genome. *Proc. Natl. Acad. Sci. USA* 2016, 113, 13378–13383.

18. Boeras, I.; Seufzer, B.; Brady, S.; Rendahl, A.; Heng, X.; Boris-Lawrie, K. The basal translation rate of authentic HIV-1 RNA is regulated by 5′UTR nt-pairings at junction of R and US. *Sci. Rep.* 2017, 7, 6902. [CrossRef]

19. Ding, P.; Kharytonchyk, Y.; Kuo, N.; Cannistraci, E.; Flores, H.; Chaudhary, R.; Sarkar, M.; Dong, X.; Telesnitsky, A.; Summers, M.F. 5′-Cap sequestration is an essential determinant of HIV-1 genome packaging. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2112475118. [CrossRef]

20. Singh, G.; Seufzer, B.; Song, Z.; Zucko, D.; Heng, X.; Boris-Lawrie, K. HIV-1 hypermethylated guanosine cap licenses specialized translation unaffected by mTOR. *Proc. Natl. Acad. Sci. USA* 2022, 119, e2105153118. [CrossRef]

21. Wada, T.; Takagi, T.; Yamaguchi, Y.; Watanabe, D.; Handa, H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II elongation. *Cell* 1999, 97, 41–51. [CrossRef]

22. Wada, T.; Takagi, T.; Yamaguchi, Y.; Watanabe, D.; Handa, H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II elongation. *Cell* 1999, 97, 41–51. [CrossRef]

23. Yamaguchi, Y.; Takagi, T.; Wada, T.; Ferdous, A.; Imai, T.; Hirose, S.; Sugimoto, S.; Yano, K.; Hartzog, G.A.; Winston, F.; et al. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. *Genes Dev.* 1998, 12, 343–356. [CrossRef]

24. Wada, T.; Takagi, T.; Yamaguchi, Y.; Watanabe, D.; Handa, H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II elongation in vitro. *EMBO J.* 1998, 17, 7935–7943. [CrossRef]

25. Komarnitsky, P.; Cho, E.-J.; Buratowski, S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. *Genes Dev.* 1998, 12, 345–356. [CrossRef]

26. Furuichi, Y. Discovery of m7G-cap in eukaryotic mRNAs. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 2015, 91, 394–409. [CrossRef]

27. Gonatopoulos-Pournatzis, T.; Cowling, V.H. Cap-binding complex (CBC). *Biochem. J.* 2010, 437, 231–242. [CrossRef]

28. Ramanathan, A.; Robb, G.B.; Chan, S.-H. mRNA capping: Biological functions and applications. *Biochem. J.* 2015, 463, 13, 774–1779. [CrossRef] [PubMed]

29. Pillutla, R.C.; Shimamoto, A.; Furuichi, Y.; Shatkin, A.J. Human mRNA Capping Enzyme (RNGTT) and Cap Methyltransferase (NMRT) Map to 6q16 and 18p11.22–p11.23, Respectively. *Genomics* 1998, 54, 351–353. [CrossRef]

30. Varshney, D.; Petit, A.-P.; Bueren-Calaguia, J.A.; Jansen, C.; Fletcher, D.A.; Peggie, M.; Weidlich, S.; Scullion, P.; Pisiakov, A.; Cowling, V.H. Molecular basis of RNA guanine-7 methyltransferase (RNMT) activation by RAM. *Nucleic Acids Res.* 2016, 44, 10423–10436. [CrossRef] [PubMed]

31. Mao, X.; Schwer, B.; Shuman, S. Yeast mRNA cap methyltransferase is a 50-kilodalton protein encoded by an essential gene. *Mol. Cell. Biol.* 1995, 15, 4167–4174. [CrossRef]

32. Cowling, V.H. Regulation of mRNA cap methylation. *Biochem. J.* 2010, 425, 295–302. [CrossRef]

33. Fabrega, C.; Haussmann, S.; Shen, V.; Shuman, S.; Lima, C.D. Structure and Mechanism of mRNA Cap (Guanine-N7) Methyltransferase. *Mol. Cell* 2004, 13, 77–89. [CrossRef]

34. Kachaev, Z.M.; Lebedeva, L.A.; Kozlov, E.N.; Shidlovskii, Y.V. Interplay of mRNA capping and transcription machineries. *Biosci. Rep.* 2020, 40, BSR20192825. [CrossRef] [PubMed]

35. Cho, E.-J.; Kobor, M.S.; Kim, M.; Greenblatt, J.; Buratowski, S. Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. *Genes Dev.* 2001, 15, 3319–3329. [CrossRef] [PubMed]

36. Ivanov, D.; Kwak, Y.T.; Guo, J.; Gaynor, R.B. Domains in the SPT5 Protein That Modulate Its Transcriptional Regulatory Properties. *Mol. Cell. Biol.* 2000, 20, 2970–2983. [CrossRef]

37. Kim, J.B.; Sharp, P.A. Positive Transcription Elongation Factor b Phosphorylates hSPT5 and RNA Polymerase II Carboxyl-terminal Domain Independently of Cyclin-dependent Kinase-activating Kinase. *J. Biol. Chem.* 2001, 276, 12317–12323. [CrossRef] [PubMed]

38. Guiguen, A.; Soutourina, J.; Dewez, M.; Tafoveau, L.; Dieu, M.; Raes, M.; Vandenhauve, J.; Werner, M.; Hermand, D. Recruitment of P-TEFb (Cdk9-Pch1) by chromatin to the cap-methyl transferase Pcm1 in fission yeast. *EMBO J.* 2007, 26, 1552–1559. [CrossRef] [PubMed]
39. Lenasi, T.; Peterlin, B.M.; Barboric, M. Cap-binding protein cloaking pre-mRNA capping to link transcription elongation and alternative splicing through positive transcription elongation factor b (P-TEFb). *J. Biol. Chem.* 2011, 286, 22758–22768. [CrossRef]

40. Mandal, S.S.; Chu, C.; Wada, T.; Handa, H.; Shatkin, A.J.; Reinberg, D. Functional interactions of RNA-capping enzyme with factors that positively and negatively regulate promoter escape by RNA polymerase II. *Proc. Natl. Acad. Sci. USA* 2004, 101, 7572–7577. [CrossRef]

41. Worch, R.; Niedzwiecka, A.; Stepinski, J.; Mazza, C.; Jankowska-Anyszka, M.; Darzynkiewicz, E.; Cusack, S.; Stolarski, R. Specificity of recognition of mRNA 5′ cap by human nuclear cap-binding complex. *RNA* 2005, 11, 1355–1363. [CrossRef]

42. Hsin, J.-P.; Manley, J.L. The RNA polymerase II CTD coordinates transcription and RNA processing. *Genes Dev.* 2012, 26, 2119–2137. [CrossRef]

43. Pan, T.; Artsimovitch, I.; Fang, X.-W.; Landick, R.; Sosnick, T.R. Folding of a large ribozyme during transcription and the effect of the elongation factor NusA. *Proc. Natl. Acad. Sci. USA* 1999, 96, 9545–9550. [CrossRef] [PubMed]

44. Schulze, W.M.; Stein, F.; Rettel, M.; Nanao, M.; Cusack, S. Structural analysis of human ARS2 as a platform for co-transcriptional RNA sorting. *Nat. Commun.* 2018, 9, 1701. [CrossRef] [PubMed]

45. Andersen, P.R.; Domanski, M.; Kristiansen, M.S.; Storvall, H.; Ntini, E.; Poser, I.; Hallais, M.; et al. The human cap-binding complex is functionally connected to the nuclear RNA exosome. *Nat. Struct. Mol. Biol.* 2013, 20, 1367–1376. [CrossRef] [PubMed]

46. Lubas, M.; Andersen, P.R.; Schein, A.; Dziembowski, A.; Kudla, G.; Jensen, T.H. The Human Nuclear Exosome Targeting Complex Is Loaded onto Newly Synthesized Transcripts to Direct Early Ribonuclease. *Cell Rep.* 2015, 10, 178–192. [CrossRef] [PubMed]

47. Palangat, M.; Meier, T.I.; Keene, R.G.; Landick, R. Transcriptional Pausing at +62 of the HIV-1 Nascent RNA Modulates Formation of the TAR RNA Structure. *Mol. Cell* 1998, 1, 1033–1042. [CrossRef]

48. Srinivasan, P.; Piano, F.; Shatkin, A.J. mRNA Capping Enzyme Requirement for Caenorhabditis elegans Viability. *J. Biol. Chem.* 2003, 278, 14168–14173. [CrossRef]

49. Shafer, B.; Chu, C.; Shatkin, A.J. Human mRNA Cap Methyltransferase: Alternative Nuclear Localization Signal Motifs Ensure Nuclear Localization Required for Viability. *Mol. Cell. Biol.* 2005, 25, 2644–2649. [CrossRef]

50. Lubas, M.; Andersen, P.R.; Schein, A.; Dziembowski, A.; Kudla, G.; Jensen, T.H. The Human Nuclear Exosome Targeting Complex Is Loaded onto Newly Synthesized Transcripts to Direct Early Ribonuclease. *Cell Rep.* 2015, 10, 178–192. [CrossRef] [PubMed]

51. Zhou, M.; Deng, L.; Kashanchi, F.; Brady, J.N.; Shatkin, A.J.; Kumar, A. The Tat/TAR-dependent phosphorylation of RNA by viral Vpr protein-mediated degradation of PCIF1. *Nat. Struct. Mol. Biol.* 2015, 22, 4756–4768. [CrossRef] [PubMed]

52. Massenet, S.; Mougin, A.; Branlant, C. Posttranscriptional Modifications in the U Small Nuclear RNAs. In *Posttranscriptional Modification and Editing*; Bujnicki, J.M., Ed.; American Society for Microbiology: Washington, DC, USA, 2014; pp. 201–227.

53. Izaurralde, E.; Lewis, J.; McGuigan, C.; Jankowska, M.; Darzynkiewicz, E.; Mattaj, I.W. A nuclear cap binding protein complex involved in pre-mRNA splicing. *Cell* 1994, 78, 657–668. [CrossRef]

54. Pabis, M.; Neufeld, N.; Steiner, M.C.; Bojic, T.; Shav-Tal, Y.; Neugebauer, K.M. The nuclear cap-binding complex interacts with the U4/U6-U5 tri-snRNP and promotes spliceosome assembly in mammalian cells. *RNA* 2013, 18, 1054–1063. [CrossRef] [PubMed]

55. Zhou, M.; Deng, L.; Kashanchi, F.; Brady, J.N.; Shatkin, A.; Kumar, A. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. *Proc. Natl. Acad. Sci. USA* 2003, 100, 12666–12671. [CrossRef]

56. Huang, B.H.; Shaw, G.M.; Arya, S.; Popovic, M.; Gallo, R.C.; Wong-Staal, F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature* 1984, 312, 166–169. [CrossRef] [PubMed]
66. Muesing, M.A.; Smith, D.H.; Cabradilla, C.D.; Benton, C.V.; Lasky, L.A.; Capon, D.J. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. *Nature* **1985**, *313*, 450–458. [CrossRef]

67. Menees, T.M.; Müller, B.; Kräusslich, H.-G. The Major 5′ End of HIV Type 1 RNA Corresponds to G456. *AIDS Res. Hum. Retrovir.* **2007**, *23*, 1042–1048. [CrossRef]

68. Nikolaičik, O.A.; Liu, S.; Kitzrow, J.P.; Liu, Y.; Rawson, J.M.O.; Shaka, S.; Cheng, Z.; Pathak, V.K.; Hu, W.-S.; Musier-Forsyth, K. Selective packaging of HIV-1 RNA genome is guided by the stability of 5′ untranslated region polyA stem. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2025769118. [CrossRef]

69. Yurkovetskiy, L.; Guney, M.H.; Kim, K.; Goh, S.L.; McCauley, S.; Dauphin, A.; Diehl, W.E.; Luban, J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. *Nat. Microbiol.* **2018**, *3*, 1354–1361. [CrossRef]

70. Dowling, J.R.O.; Topisirovic, I.; Alain, T.; Bidinosti, M.; Fonseca, B.D.; Petroulakis, E.; Wang, X.; Larsson, O.; Selvaraj, A.; Liu, Y.; et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. *Science* **2010**, *328*, 1172–1176. [CrossRef]

71. Sonenberg, N. eIF4E, the mRNA cap-binding protein: From basic discovery to translational research. *Biochem. Cell Biol.* **2008**, *86*, 178–183. [CrossRef]

72. Thoreen, C.C.; Chantranupong, L.; Keys, H.R.; Wang, T.; Gray, N.S.; Graber, T.E.; Ungureanu, N.H.; Andrews, M.; Holcik, M. The eIF4G homolog DAP5/p97 supports the translation of select mRNAs during endoplasmic reticulum stress. *Mol. Cell. Biol.* **2016**, *36*, 374–384. [CrossRef] [PubMed]

73. Fritz, S.; Boris-Lawrie, K. The RNPs of eukaryotic translation control. *Trends Cell Mol. Biol.* **2015**, *10*, 105–130. [CrossRef]

74. Ringeard, M.; Marchand, V.; Decroly, E.; Motorin, Y.; Bennasser, Y. YFTS3 is an RNA 2′-O-methyltransferase recruited by HIV to avoid innate immune sensing. *Nature* **2019**, *565*, 500–504. [CrossRef] [PubMed]

75. Sharma, A.; Yilmaz, A.; Marsh, K.; Cochrane, A.; Boris-Lawrie, K. Thriving under Stress: Selective Translation of HIV-1 Structural Protein mRNAs during Vpr-Mediated Impairment of eIF4E Translation Activity. *PLoS Pathog.* **2012**, *8*, e1002612. [CrossRef]

76. Mamane, Y.; Petroulakis, E.; LeBacquer, O.; Sonenberg, N. mTOR, translation initiation and cancer. *Oncoogene* **2006**, *25*, 6416–6422. [CrossRef]

77. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [CrossRef] [PubMed]

78. Weiss, B.; Allen, G.E.; Kloehn, J.; Abid, K.; Jaquier-Gubler, P.; Curran, J.A. eIF4E3 forms an active eIF4E complex during stresses (eIF4FS) targeting mTOR and re-programs the translatome. *Nucleic Acids Res.* **2021**, *49*, 5159–5176. [CrossRef] [PubMed]

79. Joshi, B.; Lee, K.; Maeder, D.L.; Jagus, R. Phylogenetic analysis of eIF4E-family members. *BMC Evol. Biol.* **2005**, *5*, 48. [CrossRef] [PubMed]

80. Osborne, M.J.; Volpon, L.; Kornblatt, J.A.; Culljovic-Kraljacic, B.; Baguet, A.; Borden, K.L.B. eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 3877–3882. [CrossRef]

81. Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(3′-deoxy)GpppG. *RNA* **2001**, *7*, 1486–1495. [CrossRef]

82. Landon, A.L.; Muniandy, P.A.; Shetty, A.C.; Lehrmann, E.; Volpon, L.; Houng, S.; Zhang, Y.; Dai, B.; Peroutka, R.; Mazan-Mamczarz, K.; et al. MNKS act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. *Nat. Commun.* **2014**, *5*, 5413. [CrossRef]

83. Henis-Korenblit, S.; Levy-Strumpf, N.; Goldstaub, D.; Kimchi, A. A Novel Form of DAP5 Protein Accumulates in Apoptotic Cells as a Result of Caspase Cleavage and Internal Ribosome Entry Site-Mediated Translation. *Mol. Cell. Biol.* **2000**, *20*, 496–506. [CrossRef] [PubMed]

84. Nousch, M.; Reed, V.; Bryson-Richardson, R.J.; Currie, P.D.; Preiss, T. The eIF4G–homolog p97 can activate translation independent of mTORC1-mediated regulation of mRNA translation. *RNA* **2007**, *13*, 374–384. [CrossRef] [PubMed]

85. Lewis, S.M.; Cerquozzi, S.; Graber, T.E.; Ungureanu, N.H.; Andrews, M.; Holcik, M. The eIF4G homolog DAP5/p97 supports the translation of select mRNAs during endoplasmic reticulum stress. *Nucleic Acids Res.* **2008**, *36*, 1486–1495. [CrossRef] [PubMed]

86. Lewis, S.M.; Cerquozzi, S.; Graber, T.E.; Ungureanu, N.H.; Andrews, M.; Holcik, M. The eIF4G homolog DAP5/p97 supports the translation of select mRNAs during endoplasmic reticulum stress. *Nucleic Acids Res.* **2008**, *36*, 1486–1495. [CrossRef] [PubMed]

87. Yoffe, Y.; David, M.; Kalaora, R.; Povodovski, L.; Friedlander, G.; Feldmesser, E.; Ainbinder, E.; Saada, A.; Bialik, S.; Kimchi, A. Cap-independent translation by DAP5 controls cell fate decisions in human embryonic stem cells. *Genes Dev.* **2016**, *30*, 1991–2004. [CrossRef]

88. Bukhari, S.I.A.; Truesdell, S.S.; Lee, S.; Kollu, S.; Classon, A.; Boukhali, M.; Jain, E.; Mortensen, R.D.; Yanagiya, A.; Sadreyev, R.I.; et al. A Specialized Mechanism of Translation Mediated by FXR1a-Associated MicroRNP in Cellular Quiescence. *Mol. Cell* **2016**, *61*, 760–773. [CrossRef]

89. Bukhari, S.I.A.; Vasudevan, S. FXR1a-associated microRNP: A driver of specialized non-canonical translation in quiescent conditions. *RNA Biol.* **2017**, *14*, 137–145. [CrossRef]

90. Jeong, S.J.; Park, S.; Nguyen, L.T.; Hwang, J.; Lee, E.Y.; Giong, H.K.; Lee, J.S.; Yoon, I.; Lee, J.H.; Kim, J.H.; et al. A threonyl-tRNA synthetase-mediated translation initiation machinery. *Nat. Commun.* **2019**, *10*, 1357. [CrossRef]

91. De La Parra, C.; Ernlund, A.; Alard, A.; Ruggles, K.; Ueberheide, B.; Schneider, R.J. A widespread alternate form of cap-dependent mRNA translation initiation. *Nat. Commun.* **2018**, *9*, 3068. [CrossRef]

92. Borden, K.L.B.; Volpon, L. The diversity, plasticity, and adaptability of cap-dependent translation initiation and the associated machinery. *RNA Biol.* **2020**, *17*, 1295–1291. [CrossRef]
Viruses 2022, 14, 935
117. Monette, A.; Valiente-Echeverria, F.; Rivero, M.; Cohen, É.A.; Lopez-Lastra, M.; Mouland, A.J. Dual Mechanisms of Translation Initiation of the Full-Length HIV-1 mRNA Contribute to Gag Synthesis. *PloS ONE* **2013**, *8*, e68108. [CrossRef] [PubMed]

118. Plank, T.-D.M.; Whitehurst, J.T.; Kieft, J.S. Cell type specificity and structural determinants of IRES activity from the 5′ leaders of different HIV-1 transcripts. *Nucleic Acids Res.* **2013**, *41*, 6698–6714. [CrossRef] [PubMed]

119. Vallejos, M.; Deforges, J.; Plank, T.-D.M.; Letelier, A.; Ramdohr, P.; Abraham, C.G.; Valiente-Echeverria, F.; Kieft, J.S.; Sargueil, B.; López-Lastra, M. Activity of the human immunodeficiency virus type 1 cell cycle-dependent internal ribosomal entry site is modulated by IRES trans-acting factors. *Nucleic Acids Res.* **2011**, *39*, 6186–6200. [CrossRef]

120. Gendron, K.; Ferbeyre, G.; Heveker, N.; Brakier-Gingras, L. The activity of the HIV-1 IRES is stimulated by oxidative stress and controlled by a negative regulatory element. *Nucleic Acids Res.* **2011**, *39*, 902–912. [CrossRef]

121. de Breyn, S.; Ohlmann, T. Focus on translation initiation of the HIV-1 mRNAs. *Int. J. Mol. Sci.* **2020**, *20*, 101. [CrossRef]

122. Hidalgo, L.; Swanson, C.M. Regulation of human immunodeficiency virus type 1 (HIV-1) mRNA translation. *Biochem. Soc. Trans.* **2017**, *45*, 353–364. [CrossRef]

123. Ohlmann, T.; Mengardi, C.; López-Lastra, M. Translation initiation of the HIV-1 mRNA. *Translation 2014*, *2*, e960242. [CrossRef] [PubMed]

124. Barrera, A.; Olguín, V.; Vera-Otarola, J.; López-Lastra, M. Cap-independent translation initiation of the unspliced RNA of retroviruses. *Biochim. Biophys. Acta-Gen. Regul. Mech.* **2020**, *1863*, 194583. [CrossRef] [PubMed]

125. Ohno, M.; Segref, A.; Bach, A.; Wilm, M.; Mattaj, I.W. PHAX, a mediator of U snRNA nuclear export whose activity is regulated by phosphorylation. *Cell* **2000**, *101*, 187–198. [CrossRef]

126. Hausmann, S.; Shuman, S. Specificity and Mechanism of RNA Cap Guanine-N2 Methyltransferase (Tgs1). *Cell* **2004**, *118*, 4021–4024. [CrossRef] [PubMed]

127. Huber, J.; Cronshagen, U.; Kadokura, M.; Marshallay, C.; Wada, T.; Sekine, M.; Lührmann, R. Snurportin1, an m3G-cap-specific nuclear import receptor with a novel domain structure. *EMBO J.* **1998**, *17*, 4114–4126. [CrossRef] [PubMed]

128. Mitrousis, G.; Oliia, A.S.; Walker-Kopp, N.; Cingolani, G. Molecular Basis for the Recognition of Snurportin 1 by Importin β. *J. Biol. Chem.* **2008**, *283*, 7877–7884. [CrossRef]

129. Palacios, I.; Hetzer, M.; Adam, S.A.; Mattaj, I.W. Nuclear import of U snRNPs requires importin beta. *EMBO J.* **1997**, *16*, 6783–6792. [CrossRef]

130. Narayanan, U.; Achsel, T.; Lührmann, R.; Matera, A.G. Coupled In Vitro Import of U snRNPs and SMN, the Spinal Muscular Atrophy Protein. *Mol. Cell* **2004**, *16*, 223–234. [CrossRef]

131. Jacobson, M.R.; Pederson, T. A 7-methylguanosine cap commits U3 and U8 small nuclear RNAs to the nucleolar localization pathway. *Nucleic Acids Res.* **1998**, *26*, 756–760. [CrossRef]

132. Terns, M.P.; Grimm, C.; Lund, E.; Dahlberg, J.E. A common maturation pathway for small nucleolar RNAs. *EMBO J.* **1995**, *14*, 4860–4871. [CrossRef]

133. Boulon, S.; Verheggen, C.; Jady, B.E.; Girard, C.; Pescia, C.; Paul, C.; Ospina, J.K.; Kiss, T.; Matera, A.G.; Bordonnó, A.; Loza, F.; et al. PHAX and CRM1 Are Required Sequentially to Transport U3 snoRNA to Nucleoli. *Mol. Cell* **2004**, *16*, 777–787. [CrossRef] [PubMed]

134. Pradet-Balade, B.; Girard, C.; Boulon, S.; Paul, C.; Azzag, K.; Bordonnó, R.; Bertrand, E.; Verheggen, C. CRM1 controls the composition of nucleoplasmic pre-snoRNA complexes to licence them for nucleolar transport. *EMBO J.* **2011**, *30*, 2205–2218. [CrossRef] [PubMed]

135. Verheggen, C.; Bertrand, E. CRM1 plays a nuclear role in transporting snoRNPs to nucleoli in higher eukaryotes. *Nucleus 2012*, *3*, 132–137. [CrossRef] [PubMed]

136. Monecke, T.; Dickmanns, A.; Ficner, R. Structural basis for m7G-cap hypermethylation of small nuclear, small nucleolar and telomerase RNA by the dimethyltransferase TGS1. *Nucleic Acids Res. 2009*, *37*, 3865–3877. [CrossRef]

137. Mattaj, I.W. Cap trimethylation of U snRNA is cytoplasmic and dependent on U snRNP protein binding. *Cell 1986*, *46*, 905–911. [CrossRef]

138. Yedavalli, V.S.R.K.; Jeang, K.-T. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 14787–14792. [CrossRef] [PubMed]

139. Singh, G.; Fritz, S.E.; Seufzer, B.; Boris-Lawrie, K. The mRNA encoding the human immunodeficiency virus type 1 cell cycle-dependent internal ribosomal entry site is modulated by IRES trans-acting factors. *Nucleic Acids Res.* **2013**, *41*, 6698–6714. [CrossRef] [PubMed]

140. Yin, Z.; Machius, M.; Nestler, E.J.; Rudenko, G. Activator Protein-1: Redox switch controlling structure and DNA-binding. *Nucleic Acids Res.* **2017**, *45*, 11425–11436. [CrossRef]

141. Trott-Hamici, Z.; Legrain, Y.; Bulteau, A.-L.; Chavatte, L. Selective Up-regulation of Human Selenoproteins in Response to Oxidative Stress. *J. Biol. Chem.* **2014**, *289*, 14750–14761. [CrossRef]

142. Steinbrenner, H.; Speckmann, B.; Klotz, L.-O. Selenoproteins: Antioxidant selenoenzymes and beyond. *Arch. Biochem. Biophys.* **2016**, *595*, 113–119. [CrossRef]

143. Wurtz, L.; Gribling-Burrer, A.-S.; Verheggen, C.; Leichter, M.; Takeuchi, A.; Baudrey, S.; Martin, F.; Krol, A.; Bertrand, E.; Allmang, C. Hypermethylated-capped selenoprotein mRNAs in mammals. *Nucleic Acids Res.* **2014**, *42*, 8663–8677. [CrossRef] [PubMed]

144. Guillin, O.M.; Vindry, C.; Ohlmann, T.; Chavatte, L. Interplay between Selenium, Selenoproteins and HIV-1 Replication in Human CD4 T-Lymphocytes. *Int. J. Mol. Sci.* **2022**, *23*, 1394. [CrossRef] [PubMed]

145. Bulteau, A.-L.; Chavatte, L. Update on Selenoprotein Biosynthesis. *Antioxid. Redox Signal.* **2015**, *23*, 775–794. [CrossRef] [PubMed]
146. Stone, C.A.; Kawai, K.; Kupka, R.; Fawzi, W.W. Role of selenium in HIV infection. *Nutr. Rev.* **2010**, *68*, 671–681. [CrossRef]
147. Di Bella, S.; Grilli, E.; Cataldo, M.A.; Petrosillo, N. Selenium Deficiency and HIV Infection. *Infect. Dis. Rep.* **2010**, *2*, 56–63. [CrossRef]
148. Muzembo, B.A.; Ngatu, N.R.; Januka, K.; Huang, H.L.; Nattadech, C.; Suzuki, T.; Wada, K.; Ikeda, S. Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials. *Clin. Nutr. ESPEN* **2019**, *34*, 1–7. [CrossRef]
149. Kamwesiga, J.; Mutabazi, V.; Kayumba, J.; Tayari, J.-C.K.; Smyth, R.; Fay, H.; Umurerwa, A.; Baziruwiba, M.; Ntuzimira, C.; Murebwayire, A.; et al. Effect of selenium supplementation on CD4 T-cell recovery, viral suppression, morbidity and quality of life of HIV-infected patients in Rwanda: Study protocol for a randomized controlled trial. *Trials* **2011**, *12*, 192. [CrossRef]
150. Butsch, M.; Hull, S.; Wang, Y.; Roberts, T.M.; Boris-Lawrie, K. The 5′ RNA Terminus of Spleen Necrosis Virus Contains a Novel Posttranscriptional Control Element That Facilitates Human Immunodeficiency Virus Rev/RRE-Independent Gag Production. *J. Virol.* **1999**, *73*, 4847–4855. [CrossRef]
151. Roberts, T.M.; Boris-Lawrie, K. Primary sequence and secondary structure motifs in spleen necrosis virus RU5 confer transla-tional utilization of unspliced human immunodeficiency virus type 1 reporter RNA. *J. Virol.* **2003**, *77*, 11973–11984. [CrossRef]
152. Roberts, T.M.; Boris-Lawrie, K. The 5′ RNA Terminus of Spleen Necrosis Virus Stimulates Translation of Nonviral mRNA. *J. Virol.* **2000**, *74*, 10229–10235. [CrossRef]
153. Hull, S.; Boris-Lawrie, K. RU5 of Mason-Pfizer Monkey Virus 5′ Long Terminal Repeat Enhances Cytoplasmic Expression of Human Immunodeficiency Virus Type 1 gag-pol and Nonviral Reporter RNA. *J. Virol.* **2002**, *76*, 10211–10218. [CrossRef] [PubMed]
154. Bolinger, C.; Yilmaz, A.; Hartman, T.R.; Kovacic, M.B.; Fernandez, S.; Ye, J.; Forget, M.; Green, P.L.; Boris-Lawrie, K. RNA helicase A interacts with divergent lymphotropic retroviruses and promotes translation of human T-cell leukemia virus type 1. *Nucleic Acids Res.* **2007**, *35*, 2629–2642. [CrossRef] [PubMed]
155. Stake, M.; Singh, D.; Singh, G.; Hernandez, J.M.; Maldonado, R.K.; Parent, L.J.; Boris-Lawrie, K. HIV-1 and two avian retroviral 5′ untranslated regions bind orthologous human and chicken RNA binding proteins. *Virology* **2015**, *468*, 307–320. [CrossRef] [PubMed]
156. Singh, G.; Heng, X.; Boris-Lawrie, K. Cellular RNA Helicases Support Early and Late Events in Retroviral Replication. In *Retrovirus-Cell Interactions*; Elsevier BV: Amsterdam, The Netherlands, 2018; pp. 253–271.
157. Hartman, T.R.; Qian, S.; Bolinger, C.; Fernandez, S.; Schoenberg, D.R.; Boris-Lawrie, K. RNA helicase A is necessary for translation of selected messenger RNAs. *Nat. Struct. Mol. Biol.* **2006**, *13*, 509–516. [CrossRef] [PubMed]
158. Bolinger, C.; Sharma, A.; Singh, D.; Yu, L.; Boris-Lawrie, K. RNA helicase A modulates translation of HIV-1 and infectivity of progeny virions. *Nucleic Acids Res.* **2010**, *38*, 1686–1696. [CrossRef]
159. Singh, G.; Fritz, S.M.; Ranji, A.; Singh, D.; Boris-Lawrie, K. Isolation of Cognate RNA-protein Complexes from Cells Using Oligonucleotide-directed Elution. *J. Vis. Exp.* **2017**, e54391. [CrossRef]
160. Song, Z.; Gremminger, T.; Singh, G.; Cheng, Y.; Li, J.; Qiu, L.; Ji, J.; Lange, M.J.; Zuo, X.; Chen, S.-J.; et al. The three-way junction structure of the HIV-1 PBS-segment binds host enzyme important for viral infectivity. *Nucleic Acids Res.* **2021**, *49*, 5925–5942. [CrossRef] [PubMed]
161. Boeras, I.; Song, Z.; Moran, A.; Franklin, J.; Brown, W.C.; Johnson, M.; Boris-Lawrie, K.; Heng, X. DHX9/RHA Binding to the PBS-Segment of the Genomic RNA during HIV-1 Assembly Bolsters Virion Infectivity. *J. Mol. Biol.* **2016**, *428*, 2418–2429. [CrossRef]
162. Gebhardt, A.; Habjan, M.; Benda, C.; Meiller, A.; Haas, D.A.; Hein, M.Y.; Mann, A.; Mann, M.; Habermann, B.; Pichlmair, A. mRNA export through an additional cap-binding complex consisting of NCBP1 and NCBP3. *Nat. Commun.* **2015**, *6*, 8192. [CrossRef]
163. Arrigo, S.J.; Chen, I.S.Y. Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vir, vpr, and env/vpu 2 RNAs. *Gens Dev.* **1991**, *5*, 808–819. [CrossRef]
164. D’Agostino, D.M.; Felber, B.K.; Harrison, J.E.; Pavlakis, G.N. The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. *Mol. Cell. Biol.* **1992**, *12*, 1375–1386. [PubMed]
165. Soto-Rifo, R.; Rubilar, P.S.; Ohlmann, T. The DEAD-box helicase DDX3 substitutes for the cap-binding protein eIF4E to promote compartmentalized translation initiation of the HIV-1 genomic RNA. *Nucleic Acids Res.* **2013**, *41*, 6286–6299. [CrossRef] [PubMed]
166. Kaye, J.F.; Lever, A.M.L. Human Immunodeficiency Virus Types 1 and 2 Differ in the Predominant Mechanism Used for Selection of Genomic RNA for Capsidation. *J. Virol.* **1999**, *73*, 3023–3031. [CrossRef] [PubMed]
167. Butsch, M.; Boris-Lawrie, K. Translation Is Not Required to Generate Virion Precursor RNA in Human Immunodeficiency Virus Type 1-Infected T Cells. *J. Virol.* **2000**, *74*, 11531–11537. [CrossRef]
168. McBride, M.S.; Schwartz, M.D.; Panganiban, A.T. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation. *J. Virol.* **1997**, *71*, 4544–4554. [CrossRef]
169. Dundy, M.; Leno, G.H.; Hammerskjold, M.L.; Rekosh, D.; Helga-Maria, C.; Olson, M.O.J. The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein. *J. Cell Sci.* **1995**, *108*, 2811–2823. [CrossRef]
170. Arizala, J.A.C.; Takahashi, M.; Burnett, J.C.; Ouellet, D.L.; Li, H.; Rossi, J.J. Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles. *AIDS Res. Hum. Retrovir.* **2018**, *34*, 961–981. [CrossRef]
171. Pal, V.K.; Agrawal, R.; Rakshit, S.; Shekar, P.; Murthy, D.T.N.; Vyakarnam, A.; Singh, A. Hydrogen sulfide blocks HIV rebound by maintaining mitochondrial bioenergetics and redox homeostasis. *eLife* **2021**, *10*, e68487. [CrossRef]
172. Shytaj, I.L.; Procopio, F.A.; Tarek, M.; Carlon-Andres, I.; Tang, H.; Goldman, A.R.; Munshi, M.; Pal, V.K.; Forcato, M.; Sreeram, S.; et al. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. *EMBO Mol. Med.* **2021**, *13*, e13901. [CrossRef]

173. Acchioni, C.; Palermo, E.; Sandini, S.; Acchioni, M.; Hiscott, J.; Sgarbanti, M. Fighting HIV-1 persistence: At the crossroads of “shoc-K and B-Lock”. *Pathogens* **2021**, *10*, 1517. [CrossRef]

174. Osmer, P.S.; Singh, G.; Boris-Lawrie, K. A New Approach to 3D Modeling of Inhomogeneous Populations of Viral Regulatory RNA. *Viruses* **2020**, *12*, 1108. [CrossRef] [PubMed]

175. Obayashi, C.M.; Shinohara, Y.; Masuda, T.; Kawai, G. Influence of the 5'-terminal sequences on the 5'-UTR structure of HIV-1 genomic RNA. *Sci. Rep.* **2021**, *11*, 10920. [CrossRef] [PubMed]

176. Ye, L.; Gribling-Burrer, A.-S.; Bohn, P.; Kibe, A.; Börtlein, C.; Ambi, U.B.; Ahmad, S.; Olguin-Nava, M.; Smith, M.; Caliskan, N.; et al. Short- and long-range interactions in the HIV-1 5' UTR regulate genome dimerization and packaging. *Nat. Struct. Mol. Biol.* **2022**, *29*, 306–319. [CrossRef] [PubMed]